ADMA Biologics, headquartered in Ramsey, New Jersey, specializes in manufacturing FDA-approved plasma-derived biologics for immune deficiencies and infectious diseases, employing 624 staff. The company went public on October 17, 2013.
Adma Biologics (ADMA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Adma Biologics's actual EPS was $0.15, beating the estimate of $0.14 per share, resulting in a 5.04% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
